Jasper Therapeutics
Redwood City
About Jasper Therapeutics
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for the expanded use of curative therapy with stem cell transplants and gene therapies. The company s novel engineered hematopoietic stem cells (eHSCs) platform aims to overcome the limitations of transplant grafts while also unlocking the potential of stem cells, potentially increasing the number of patients who could benefit from allogeneic and autologous gene-edited hematopoietic stem cell therapy. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $319.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:JSPR
- Website: jaspertherapeutics.com
- Phone: 650-549-1400
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/jasper-therapeutics-103206 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.